New allergy shot shows promise in early trial

NCT ID NCT07052097

Symptom relief Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested an injection called TQC2938, a humanized monoclonal antibody, in 136 adults with seasonal allergic rhinitis. All participants also used a standard nasal spray. The study measured how well the injection reduced nasal symptoms like sneezing and congestion over 2 and 4 weeks compared to a placebo. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: TQC2938 injection (a humanized monoclonal antibody)
What this could lead to: If it works, this could provide a new add-on treatment option for people with seasonal allergies who still have symptoms despite using standard nasal sprays.
What could go wrong: This is an early Phase 2 trial with only 136 participants, so results may not apply to everyone. The drug is still experimental and may not prove more effective than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

136 people

The number who actually took part.

Started

Jul 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 75 years at the screening period * Patients who met the diagnostic criteria of allergic rhinitis in Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (revised edition, 2022) * Positive of at least 1 allergen skin prick test(SPT) and/or serum-specific IgE within 1 year before enrollment. * Subjects have sufficient pollen exposure during the pollen season: * Subjects' medical history suggested that Specific Absorption Rate (SAR) symptoms were poorly controlled or subjects' subjective symptoms were not satisfactorily controlled after drug treatment during the same pollen season in the past. * On the day of screening, the iTNSS score in the morning was ≥6; At baseline visit, the morning iTNSS was ≥6 points, and the average score of the past 6 rTNSS was ≥6 points; * During the screening/induction period, the subjects had good compliance; * Subjects with asthma who were assessed by the investigator or specialist as having stable asthma; * Voluntary participation in this trial and signing the informed consent form * Subjects (including partners) have no pregnancy and voluntarily take one or more non-pharmaceutical measures for contraception at period from drug administration to 6 months after the last study drug administration. Exclusion Criteria: * Laboratory test values did not meet the requirements during screening or randomization; * Any disease that the investigator believes interferes with the patient's ability to complete the entire course of the study; * Patients with active autoimmune disease * People with known or suspected immunosuppression * Subjects with active malignancy or a history of malignancy; * History of active pulmonary tuberculosis within 12 months prior to screening; * Diagnosis of helminthic infection within 6 months prior to screening, not receiving standard treatment or not responding to standard treatment; * Subjects who have undergone nasal surgery or sinus surgery within 6 months before screening * Subjects have concomitant medical conditions that preclude them from completing the screening period assessment or evaluating the primary efficacy endpoint; * Subjects with nasal malignancies and benign tumors; * History of hypersensitivity to any content of the study drugs or its excipients * Subjects with a history of systemic allergy to any biological agent; * Pregnant or lactating women; * Alcohol, drug and known drug dependence; * Have a history of vital organ transplantation or hematopoietic stem cell/bone marrow transplantation; * Any medical or psychiatric condition that, in the investigator's judgment, puts the subject at risk, interferes with participation in the study, or interferes with the interpretation of the study results; * Any condition that the investigator or primary physician believes may not be appropriate for participating the study

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Seasonal allergic rhinitis

Contacts and locations

Locations

Affiliated Zhongshan Hospital Of Dalian university

Dalian, Liaoning, 116001, China
Baotou Central Hospital

Baotou, Inner Mongolia, 14000, China
Beijing TongRen Hospital, Capital Medical University

Beijing, Beijing Municipality, 100730, China
Cangzhou central hosipital

Cangzhou, Hebei, 061000, China
China-japan Friendship Hospital, Jilin University

Changchun, Jilin, 130033, China
First Affiliated Hospital, Heilongjang University of Chinese Medigine

Harbin, Heilongjang, 150040, China
First Hospital of Shangxi Medical University

Taiyuan, Shangxi, 30001, China
Ganzu Province People's Hospital

Lanzhou, Ganzu, 730000, China
General Hospital of Ningxia Medical University

Yinchuan, Ningxia, 750004, China
Hebei Medical University Third Hospital

Shijiazhuang, Hebei, 050000, China
Henan Provincial People's Hospital

Zhengzhou, Henan, 450002, China
Northern Jiangsu People'S Hospital

Yangzhou, Jiangsu, 225000, China
Peking University First Hospital

Beijing, Beijing Municipality, 100034, China
Peking University People's Hospital

Beijing, Beijing Municipality, 100044, China
Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China
People'S Hospital of Zhengzhou

Zhengzhou, Henan, 450002, China
Qilu Hospital of Shandong University

Jinan, Shandong, 250021, China
Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, 710004, China
Shanxi Bethune Hospital

Taiyuan, Shanxi, 030000, China
Shengjing Hospital of China Medical University

Shenyang, Liaoning, 110004, China
The First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, 650032, China
The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine

Xi'an, Shaanxi, 710089, China
The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, 830013, China
The Second People's Hospital of Shandong Province

Jinan, Shandong, 250021, China
The first hospital of Jilin University

Changchun, Jilin, 130031, China
Tianjin First Central Hospital

Tianjin, Tianjin Municipality, 300192, China
Tongji Hospital of Tongji medical college of HUST

Wuhan, Hubei, 430030, China
Yantai Yuhuangding Hospital

Yantai, Shandong, 264000, China
Zhengzhou Central Hospital

Zhengzhou, Henan, 450007, China
Zibo Central Hospital

Zibo, Shandong, 255020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.